Enoblituzumab, previously known as TJ-271 or MGA271, represents the unique monoclonal directed at CD33, a marker found predominantly on cancer tissues. Such agent operates as the dual-action molecule, at once attaching https://www.targetmol.com/compound/enoblituzumab